Western blots also failed to reveal RhoGDI1 and RhoGDI2 loss of expression in the aggressive prostate cancer cell lines that could have explained Rac1 and Cdc42 hyperactivation (Figure 1F). This evidence concerns the gene ARHGDIB and prostate cancer.